Hyper Corporation

Hyper Corporation EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Hyper Corporation (065650.KQ) as of Nov 4, 2026 is 2.62 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -1.33 B KRW — a change of -297.64% (higher).

EBITDA

2.62 BKRW

YoY

-297.64%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Hyper Corporation is 2025 2.62 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Hyper Corporation was 2024 -1.33 B KRW. It decreases by -297.64% higher compared to the previous year.

The Hyper Corporation EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2016
-3.63 B KRW
Jan 1, 2017
-11.51 B KRW
Jan 1, 2018
-5.85 B KRW
Jan 1, 2019
-2.12 B KRW
Jan 1, 2020
-1.88 B KRW
Jan 1, 2022
-12.23 B KRW
Jan 1, 2023
-1.33 B KRW
Jan 1, 2025
2.62 B KRW
The Hyper Corporation EBITDA history
YEAREBITDAYoY
2.62 BKRW-297.64%
-1.33 BKRW-89.14%
-12.23 BKRW+551.55%
-1.88 BKRW-11.33%
-2.12 BKRW-63.79%
-5.85 BKRW-49.20%
-11.51 BKRW+216.66%
-3.63 BKRW+204.58%
-1.19 BKRW-58.34%
-2.86 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hyper Corporation Stock analysis

What does Hyper Corporation do? Hyper Corporation Inc generates revenue through the Information Technology Business segment, which manufactures and sells mouses, monitors, televisions, routers, and game devices, while also operating Internet portals and specialized sites. The New Drug Business segment develops and sells non narcotic analgesics, Alzheimer's treatments, and Alzheimer's dementia diagnosis kits. The company's IT products are purchased by consumers and businesses seeking technology solutions, while the pharmaceutical products target healthcare providers and patients requiring pain management and cognitive health support. The Information Technology Business segment benefits from the sale of hardware devices and digital content services, with Internet portals and specialized sites driving user engagement and advertising revenue. The New Drug Business segment focuses on medical solutions for chronic conditions, serving both institutional and individual markets through direct sales channels. Both segments operate under the same corporate structure, leveraging the company's existing infrastructure for product development and distribution. Hyper Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hyper Corporation stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Hyper Corporation is 2.62 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Hyper Corporation changed from -1.33 B KRW to 2.62 B KRW, representing a -297.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Hyper Corporation since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Hyper Corporation historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Hyper Corporation

All Key Metrics — Hyper Corporation